Alaunos Therapeutics近日宣布,其研发的差异化非激素口服疗法Aln1003在临床前研究中取得了积极的概念验证数据。该药物针对肥胖及相关代谢疾病展现出显著的治疗潜力,为患者提供了一种创新的非激素治疗选择。
Alaunos Therapeutics近日宣布,其研发的差异化非激素口服疗法Aln1003在临床前研究中取得了积极的概念验证数据。该药物针对肥胖及相关代谢疾病展现出显著的治疗潜力,为患者提供了一种创新的非激素治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.